Information about the use of ombitasvir/paritaprevir/ritonavir/dasabuvir ± ribavirin (OBV/PTV/r/DSV ± RBV) in real-clinical practice in Latin America is scarce. We aimed to confirm safety and effectiveness of OBV/PTV/r/DSV ± RBV therapy in real-world setting. We analyzed a cohort of patients with genotype 1 infection treated with OBV/PTV/r/DSV ± RBV.
collected from 21 centers in Latin America. A total of 96 patients received OBV/PTV/r/DSV, associated with RBV in 68% of the cases. Most were genotype 1b (80%), 56 (58%) had cirrhosis, and 45 (47%) failed prior HCV treatment. Adverse events occurred in 62% of patients. The most common adverse events were pruritus (21%), hyperbilirubinemia (17%), and asthenia (17%).
Five patients discontinued therapy prematurely due to hepatic decompensation, three of them were Child-Pugh B at baseline and one patient died due to multi-organ failure. Follow up HCV-RNA 12 weeks after completion of therapy was evaluated in all the patients and sustained virologic response rate was 97%. No virologic breakthrough was detected. Our study confirms that OBV/PTV/r/DSV treatment is highly effective in patients with chronic HCV without cirrhosis or with Child-Pugh A cirrhosis in non-European populations. Adverse events were often mild and rarely led to treatment discontinuation except for patients with Child-Pugh B cirrhosis or with previous history of hepatic decompensation. These results can support the development of public strategies to expand the access of OBV/PTV/r + DSV and other DAAs combinations in order to reduce the burden of HCV infection in our region.
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| INTRODUCTION
Chronic infection with hepatitis C virus (HCV) is a major health problem in Latin America, with about 8-10 million people chronically infected with HCV in the region. 1 Nearly 30% of those infected will develop cirrhosis and/or liver cancer, which has a high mortality and a significant cost to the health system. and dasabuvir (DSV; non-nucleoside polymerase inhibitor). The efficacy and safety of OBV/PTV/r ± DSV regimen in patients without cirrhosis or with compensated cirrhosis has been demonstrated in different phase 3 clinical trials. 2, [6] [7] [8] Cure rate in this population exceeded 90% in all the subgroups with rate of severe adverse events lower than 5%.
The safety and effectiveness of OBV/PTV/r + DSV treatment has been corroborated in real-life cohorts from Europe. 9, 10 Previous reports have described lower response rates for IFNbased antiviral therapy in Latin-American patients and to our knowledge there is no information regarding the use of DAA regimens in this population. 11 Information about the use of any DAA regimen in real-world practice in Latin America is scarce.
Knowing the safety profile of the OBV/PTV/r + DSV regimen in a Latin-American cohort is relevant for treating physicians given the different race and ethnicities in this region when compared to
Europe or the United States. 
| Effectiveness
All the patients who completed OBV/PTV/r + DSV regimen presented undetectable HCV RNA 12 weeks after completion of treatment.
Overall, SVR12 was achieved by 97% (93/96) (Fig. 1) . Among those patients who completed the scheduled therapy, all achieved EOT and SVR12, with no virologic breakthrough reported. Only three patients failed to achieve SVR12. Of these, one patient discontinued therapy due to serious adverse events and one developed septic shock and died. The remaining patient discontinued treatment because of an event unrelated to HCV therapy. One patient discontinued therapy at week 7 of treatment after developing encephalopathy but still accomplished SVR12. MELD score in cirrhotic patients decreased at least 1 point between baseline and post-treatment week 12 in 41% of the cases (Fig. 2) .
| Safety
Adverse events were reported in 60 (62%) patients; most were mild and occurred more frequently in those treated with RBV ( Table 2 ). The most common adverse events were pruritus (21% of patients) and nausea (17%). Total bilirubin level >3 mg/dL was only reported in patients receiving RBV (17%). Hemoglobin drop ≥3 g/dL was observed in 23% patients. Decline in hemoglobin level below 10 g/dL was described in 6% of patients whereas values below 8 g/dL were not reported. All the patients who developed significant hemoglobin drop received RBV and in all cases anemia was managed by RBV dose reduction. During posttreatment follow up, one case of HCC was identified in a patient that had originally showed no lesion on the liver ultrasound examination at baseline.
Serious adverse events were reported in five patients who were all treated with RBV and were related with hepatic decompensation (Table 3 ). According to treating physicians, in three cases decompensation was associated with ongoing antiviral therapy. 
| DISCUSSION
In our Latin-American cohort of genotype 1 HCV-infected patients treated with OBV/PTV/r + DSV ± RBV, we observed a SVR12 rate over 97%, nearly matching the rates reported in clinical trials. 4, 7, 15 Therapy was safe and well tolerated except in those patients with CTP B or previous history of ascites and/or encephalopathy. Furthermore, the use of RBV was significantly associated with a higher incidence of adverse events.
The regimen also proved to be effective in compensated cirrhotic patients. These findings are consistent with the results of clinical trials and real-world studies. 10, [16] [17] [18] Patients co-infected with HIV were taking stable atazanavir or raltegravir-inclusive antiretroviral regimen.
No serious adverse events were reported in this subgroup but we must keep in mind that the sample size was too small to make any definitive conclusions.
Regarding the safety profile of OBV/PTV/r + DSV therapy, the majority of adverse events were mild, and strongly associated with use of RBV. Pruritus, nausea, headache, and asthenia were the most common adverse events, in agreement with the results of previous clinical trials and real-life studies. 4, 9, 10 In our study, hyperbilirubinemia and anemia were also present in patients with RBV co-administration but no ALT elevation was reported.
Decline of hemoglobin level below 10 g/dL was infrequently reported and no blood transfusions were required. Seventy percent of the patients received RBV according to the recommendations of the summary characteristics of the product.
Recently, the TURQUOISE-III trial has shown that the addition of RBV is not necessary for cirrhotic patients infected with genotype 1b and this recommendation has been incorporated by international guidelines.
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FIGURE 1 Virologic response to OBV/PTV/r/DSV ± RBV therapy Treatment with OBV/PTV/r + DSV is not recommended in patients with CTP B or C cirrhosis. 19 Post-marketing reports of hepatic decompensation were described; however, the causal association between its use and the development of liver failure has not been established. 20 In our series, CTP B patients were included before these recommendations were released by the Food and Drugs Administration and three of them developed ontreatment liver failure and one died. Two studies reported outcomes of OBV/PTV/r + DSV in patients with CTP B, although the 25 patients achieved SVR12, eight patients experienced serious adverse events. 10, 21 We suggest that in patients with current signs of hepatic functional impairment or history of hepatic decompensation, alternative therapeutic options should be evaluated.
Low-and middle-income countries account for more than 80% of the global HCV burden but most patients with HCV infection remain untreated. 22 This great disparity is the consequence of low detection rate of HCV-infected patients and the high cost of DAA therapy. Approval of second-wave DAAs in Latin America occurred 2-3 years later than in developed countries, so safety and effectiveness of these new therapies in our region is limited. Latin America lacks of adequate representative real-world cohorts concerning the use of any interferon-free regimen, either at country or regional levels.
Regional differences in the predictors of response might result in differences in real world effectiveness. For example, a recent study reported the absence of Q80K polymorphism in 114 HCVinfected patients from Argentina, a well known predictor of low response when using protease inhibitors. 
